With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.
Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine ...
A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous ...
The decision follows phase 3 trial data showing the immunotherapy cut disease recurrence or death risk by 68% in patients ...
Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
Phase III trial data support obicetrapib's lipid controlling effects in high-risk individuals without sufficient response to other lipid-lowering therapies. Obicetrapib is a highly selective CETP ...
A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...
Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback